RPHM — Reneo Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $57.82m
- -$45.15m
- 10
- 43
- 14
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | 0.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.05% | ||
| Return on Equity | -82.07% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Directors
- Mike Grey CHM
- Gregory Flesher PRE
- Niall O'donnell CFD (48)
- Vineet Jindal CFO
- Lynn Purkins VOP
- Alejandro Dorenbaum OTH
- Ashley Hall OTH (49)
- Paul Hoelscher DRC (56)
- Lon Cardon IND
- Eric Dube IND (48)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 22nd, 2014
- Public Since
- April 9th, 2021
- No. of Shareholders
- 184
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 33,420,808
- Address
- 18575 Jamboree Road, Suite 275-S, IRVINE, 92612
- Web
- https://reneopharma.com/
- Phone
- +1 8582830280
- Auditors
- Ernst & Young LLP
Upcoming Events for RPHM
Reneo Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Reneo Pharmaceuticals Inc Earnings Release
Similar to RPHM
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Reneo Pharmaceuticals share price?
As of Today at 19:18 UTC, shares in Reneo Pharmaceuticals are trading at $1.73. This share price information is delayed by 15 minutes.
How has the Reneo Pharmaceuticals share price performed this year?
Shares in Reneo Pharmaceuticals last closed at $1.73 and the price had moved by -74.18% over the past 365 days. In terms of relative price strength the Reneo Pharmaceuticals share price has underperformed the S&P500 Index by -79.15% over the past year.
What are the analyst and broker recommendations for Reneo Pharmaceuticals?
The overall consensus recommendation for Reneo Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Reneo Pharmaceuticals dividend yield?
Reneo Pharmaceuticals does not currently pay a dividend.
Does Reneo Pharmaceuticals pay a dividend?
Reneo Pharmaceuticals does not currently pay a dividend.
When does Reneo Pharmaceuticals next pay dividends?
Reneo Pharmaceuticals does not currently pay a dividend.
How do I buy Reneo Pharmaceuticals shares?
To buy shares in Reneo Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Reneo Pharmaceuticals?
As of the previous close price of $1.73, shares in Reneo Pharmaceuticals had a market capitalisation of $57.82m.
Where are Reneo Pharmaceuticals shares listed?
Here are the trading details for Reneo Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RPHM
What kind of share is Reneo Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Reneo Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Reneo Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Reneo Pharmaceuticals is $1.68. That is 2.89% below the last closing price of $1.73.
Analysts covering Reneo Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.91 for the next financial year.
What is the trend in the Reneo Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Reneo Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -80.07%.
As of the last closing price of $1.73, shares in Reneo Pharmaceuticals were trading -63.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Reneo Pharmaceuticals PE Ratio?
The Reneo Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Reneo Pharmaceuticals?
Reneo Pharmaceuticals' management team is headed by:
- Mike Grey - CHM
- Gregory Flesher - PRE
- Niall O'donnell - CFD
- Vineet Jindal - CFO
- Lynn Purkins - VOP
- Alejandro Dorenbaum - OTH
- Ashley Hall - OTH
- Paul Hoelscher - DRC
- Lon Cardon - IND
- Eric Dube - IND